CL2009000573A1 - Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo. - Google Patents
Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.Info
- Publication number
- CL2009000573A1 CL2009000573A1 CL2009000573A CL2009000573A CL2009000573A1 CL 2009000573 A1 CL2009000573 A1 CL 2009000573A1 CL 2009000573 A CL2009000573 A CL 2009000573A CL 2009000573 A CL2009000573 A CL 2009000573A CL 2009000573 A1 CL2009000573 A1 CL 2009000573A1
- Authority
- CL
- Chile
- Prior art keywords
- polysorbate
- chlorides
- preservative
- eye
- contain
- Prior art date
Links
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 title abstract 2
- 239000007900 aqueous suspension Substances 0.000 title abstract 2
- 239000006172 buffering agent Substances 0.000 title abstract 2
- 239000001768 carboxy methyl cellulose Substances 0.000 title abstract 2
- 150000001805 chlorine compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 title abstract 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 title abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 title abstract 2
- 229940068968 polysorbate 80 Drugs 0.000 title abstract 2
- 239000003755 preservative agent Substances 0.000 title abstract 2
- 230000002335 preservative effect Effects 0.000 title abstract 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 title abstract 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 title abstract 2
- 229960002117 triamcinolone acetonide Drugs 0.000 title abstract 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003002 pH adjusting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Composición farmacéutica en suspensión acuosa que no contiene preservante que comprende a) 3,5-4,5% de acetonido de triamcinolona, b) 0,45-0,55% de carboximetilcelulosa de sodio, c) 0,002-0,02% de polisorbato 80, d) cloruros para ajustar la tonicidad, e) agente tamponante, f) agua, g) agente de ajuste de Ph; útil para tratar el ojo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3545908P | 2008-03-11 | 2008-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009000573A1 true CL2009000573A1 (es) | 2010-01-04 |
Family
ID=40548758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009000573A CL2009000573A1 (es) | 2008-03-11 | 2009-03-11 | Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8128960B2 (es) |
| EP (1) | EP2262506B1 (es) |
| JP (1) | JP5581227B2 (es) |
| KR (1) | KR101555293B1 (es) |
| CN (1) | CN101959519B (es) |
| AR (1) | AR070824A1 (es) |
| AU (1) | AU2009223649B2 (es) |
| BR (1) | BRPI0909630B8 (es) |
| CA (1) | CA2717605C (es) |
| CL (1) | CL2009000573A1 (es) |
| DK (1) | DK2262506T3 (es) |
| ES (1) | ES2471122T3 (es) |
| MX (1) | MX2010009974A (es) |
| PL (1) | PL2262506T3 (es) |
| PT (1) | PT2262506E (es) |
| RU (1) | RU2481842C2 (es) |
| SI (1) | SI2262506T1 (es) |
| TW (1) | TWI468165B (es) |
| UY (1) | UY31699A1 (es) |
| WO (1) | WO2009114521A1 (es) |
| ZA (1) | ZA201005839B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| EP2262506B1 (en) * | 2008-03-11 | 2014-05-07 | Alcon Research, Ltd. | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
| AU2009330517A1 (en) * | 2008-12-22 | 2010-07-01 | Alcon Research, Ltd. | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye |
| US20120271272A1 (en) | 2010-10-15 | 2012-10-25 | Iscience Interventional Corporation | Device for ocular access |
| CN102008488B (zh) * | 2010-11-24 | 2012-10-10 | 广州固志医药科技有限公司 | 一种曲安奈德眼用制剂及其制备方法 |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| EP2916827B1 (en) * | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| SG10201702674PA (en) | 2013-05-03 | 2017-06-29 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
| EP3003454B1 (en) | 2013-06-03 | 2020-01-08 | Clearside Biomedical, Inc. | Apparatus for drug delivery using multiple reservoirs |
| RU2710491C2 (ru) | 2014-06-20 | 2019-12-26 | Клиасайд Байомедикал, Инк. | Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань |
| US9694145B1 (en) | 2016-03-29 | 2017-07-04 | Joseph Onorato | Auto-injector systems and method for delivering cyst medication on demand |
| CA3062845A1 (en) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
| EP3496680B1 (en) | 2016-08-12 | 2024-10-02 | Clearside Biomedical, Inc. | Device for adjusting the insertion depth of a needle for medicament delivery |
| WO2018204515A1 (en) | 2017-05-02 | 2018-11-08 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
| WO2019136512A1 (en) * | 2018-01-10 | 2019-07-18 | Eye Co Pty Ltd | Medical device and pharmaceutical composition for treatment of an eye disease or condition |
| USD893715S1 (en) | 2018-11-06 | 2020-08-18 | Joseph Onorato | Measurement guide for a cyst, lesion or skin disorder |
| WO2020214799A1 (en) * | 2019-04-16 | 2020-10-22 | Clearside Biomedical, Inc. | Injectable triamcinolone formulations |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| CN114010593A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种曲安奈德混悬注射液及制备方法 |
| CN115969784B (zh) * | 2022-12-26 | 2025-10-21 | 昆明积大制药股份有限公司 | 曲安奈德注射液的制备方法 |
| WO2025114562A1 (en) * | 2023-11-30 | 2025-06-05 | Institut National de la Santé et de la Recherche Médicale | Intravitreal spironolactone suspension |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3962430A (en) * | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
| US4370325A (en) * | 1979-03-30 | 1983-01-25 | Dermik Laboratories | Pharmaceutical compositions and method of treatment |
| US4432964A (en) * | 1981-08-24 | 1984-02-21 | Alza Corporation | Topical composition containing steroid in two forms released independently from polymeric carrier |
| US5164190A (en) * | 1990-12-11 | 1992-11-17 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| WO1996020712A1 (en) | 1994-12-30 | 1996-07-11 | American Home Products Corporation | Clear non-alcoholic hydrocortisone solutions |
| CA2336703A1 (en) | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
| AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
| AUPQ496500A0 (en) | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| US6395294B1 (en) | 2000-01-13 | 2002-05-28 | Gholam A. Peyman | Method of visualization of the vitreous during vitrectomy |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| ES2396598T3 (es) * | 2000-08-25 | 2013-02-22 | Senju Pharmaceutical Co., Ltd. | Preparaciones en forma de suspensiones acuosas |
| EP1414466B1 (en) * | 2001-07-09 | 2009-08-19 | CombinatoRx, Incorporated | Combinations for the treatment of inflammatory disorders |
| US20030129242A1 (en) | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
| CA2516782A1 (en) | 2003-02-20 | 2004-09-02 | Alcon, Inc. | Use of steroids to treat ocular disorders |
| US20040186084A1 (en) | 2003-03-21 | 2004-09-23 | Akorn, Inc. | Triamcinolone formulations and methods for their preparation and use |
| CA2539023A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20060141049A1 (en) | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| JP2007516297A (ja) * | 2003-12-23 | 2007-06-21 | アルザ・コーポレーシヨン | 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物 |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| WO2005115411A1 (ja) | 2004-05-31 | 2005-12-08 | Senju Pharmaceutical Co, .Ltd. | 透明組織可視化剤 |
| US8246949B2 (en) | 2004-10-27 | 2012-08-21 | Aciont, Inc. | Methods and devices for sustained in-vivo release of an active agent |
| EP1827378A2 (en) | 2004-11-17 | 2007-09-05 | Government of The United States of America, as represented by Secretary, Department of Health and Human Services | Steroid formulation and methods of treatment using same |
| EP1867334A4 (en) * | 2005-02-18 | 2009-07-15 | Santen Pharmaceutical Co Ltd | METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| ITRM20050547A1 (it) | 2005-11-04 | 2007-05-05 | Sooft Italia S R L | Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico. |
| EP2262506B1 (en) * | 2008-03-11 | 2014-05-07 | Alcon Research, Ltd. | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
-
2009
- 2009-03-10 EP EP09720520.7A patent/EP2262506B1/en active Active
- 2009-03-10 CN CN2009801076823A patent/CN101959519B/zh active Active
- 2009-03-10 RU RU2010141542/15A patent/RU2481842C2/ru active
- 2009-03-10 KR KR1020107022609A patent/KR101555293B1/ko active Active
- 2009-03-10 MX MX2010009974A patent/MX2010009974A/es active IP Right Grant
- 2009-03-10 ES ES09720520.7T patent/ES2471122T3/es active Active
- 2009-03-10 US US12/401,168 patent/US8128960B2/en active Active
- 2009-03-10 SI SI200930950T patent/SI2262506T1/sl unknown
- 2009-03-10 WO PCT/US2009/036652 patent/WO2009114521A1/en not_active Ceased
- 2009-03-10 PT PT97205207T patent/PT2262506E/pt unknown
- 2009-03-10 BR BRPI0909630A patent/BRPI0909630B8/pt active IP Right Grant
- 2009-03-10 DK DK09720520.7T patent/DK2262506T3/da active
- 2009-03-10 PL PL09720520T patent/PL2262506T3/pl unknown
- 2009-03-10 UY UY31699A patent/UY31699A1/es not_active Application Discontinuation
- 2009-03-10 AU AU2009223649A patent/AU2009223649B2/en active Active
- 2009-03-10 CA CA2717605A patent/CA2717605C/en active Active
- 2009-03-10 TW TW98107670A patent/TWI468165B/zh active
- 2009-03-10 JP JP2010550813A patent/JP5581227B2/ja active Active
- 2009-03-11 CL CL2009000573A patent/CL2009000573A1/es unknown
- 2009-03-11 AR ARP090100862A patent/AR070824A1/es unknown
-
2010
- 2010-08-16 ZA ZA2010/05839A patent/ZA201005839B/en unknown
-
2012
- 2012-01-17 US US13/352,009 patent/US8211880B2/en active Active
- 2012-01-17 US US13/352,043 patent/US20120115829A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000573A1 (es) | Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo. | |
| CL2013002467A1 (es) | Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular. | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| BRPI0508403A (pt) | produtos de pelìcula tendo propriedades de desintegração controlada | |
| CR11167A (es) | Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos | |
| PL1933809T3 (pl) | Kompozycje do dostarczania donosowego | |
| WO2009028495A1 (ja) | 真菌性皮膚炎用剤 | |
| CL2010001406A1 (es) | Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion. | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| AR082381A1 (es) | Composicion acuosa que contiene bromhexina | |
| NZ708247A (en) | Hyaluronic acid based formulations | |
| CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
| IT1392903B1 (it) | Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie | |
| AR081520A1 (es) | Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo | |
| ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
| BR112012015449A2 (pt) | suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica | |
| NO20091517L (no) | Emulsjon | |
| CL2008002758A1 (es) | Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento. | |
| WO2007037905A3 (en) | Pesticide strips for control of mites in honeybees | |
| TR201101807T2 (tr) | Rosuvastatin kalsiyumun farmasotik bileşimleri | |
| CL2009000986A1 (es) | Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma | |
| EA201000330A1 (ru) | Способ повышения значения ph кислых водоемов | |
| CL2012001545A1 (es) | Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras. | |
| DE602006019320D1 (de) | Biologisch wirksame zusammensetzung mit ethylcellulose |